Twenty four-week peginterferon plus ribavirin after interferon-&beta; induction for genotype 1b chronic hepatitis C

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

277

HTML

3204

Figures (1-3)

268

Tables (1-4)

270

Sum=4019

Jun 27, 2010 (publication date) through Jan 25, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Hepatol. Jun 27, 2010; 2(6): 226-232
Published online Jun 27, 2010. doi: 10.4254/wjh.v2.i6.226

Table 2 Clinical background by therapeutic response

	Dosing duration of peginterferon plus ribavirin
	1-24 wk		20-24 wk
	SVR non-SVR	P value	SVR non-SVR	P value
n of patients	21		17
n of patients	40		14
Male [n (%)]	12 (57)	0.0636^b	10 (59)	0.1493^c
Male [n (%)]	13 (33)	0.0636^b	4 (29)	0.1493^c
Age (yr)	58 (35-74)	0.0030^a	58 (35-74)	0.0134^a
Age (yr)	65 (37-78)	0.0030^a	63 (58-71)	0.0134^a
Body weight > 60 kg [n (%)]	13 (62)	0.0441^b	10 (59)	0.0669^c
Body weight > 60 kg [n (%)]	14 (35)	0.0441^b	3 (21)	0.0669^c
HCV-RNA (Log IU/mL)	5.8 (5.1-6.9)	0.1685^a	6.0 (5.2-6.9)	0.9967^a
HCV-RNA (Log IU/mL)	6.1 (5.1-7.2)	0.1685^a	6.1 (5.2-6.6)	0.9967^a
Alanine amino-transferase (U/L)	97 (52-269)	0.7699^a	86 (57-138)	0.6410^a
Alanine amino-transferase (U/L)	93 (27-513)	0.7699^a	80 (28-260)	0.6410^a
Platelet count (× 10⁴/μL)	16.8 (10.9-30.6)	0.0020^a	17.0 (10.9-30.6)	0.0007^a
Platelet count (× 10⁴/μL)	13.3 (9.1-24.0)	0.0020^a	11.4 (9.1-15.4)	0.0007^a
Albumin (g/dL)	3.9 (3.5-4.4)	0.7410^a	3.9 (3.5-4.2)	0.9211^a
Albumin (g/dL)	3.9 (3.5-4.5)	0.7410^a	3.9 (3.5-4.5)	0.9211^a
Hemoglobin (g/dL)	14.4 (11.4-15.4)	0.0126^a	14.5 (11.4-15.4)	0.1379^a
Hemoglobin (g/dL)	13.1 (10.5-15.4)	0.0126^a	13.5 (10.7-15.4)	0.1379^a
Interferon-naïve [n (%)]	12 (57)	0.6847^b	9 (53)	0.8150^b
Interferon-naïve [n (%)]	25 (63)	0.6847^b	8 (57)	0.8150^b
Peginterferon-α2a/-α2b (n)	12/9	0.2016^b	9/8	0.4607^c
Peginterferon-α2a/-α2b (n)	16/24	0.2016^b	10/4	0.4607^c
Dosing duration of peginterferon (wk)	24 (4-24)	0.0009^a	24 (21-24)	0.5082^a
Dosing duration of peginterferon (wk)	15 (2-24)	0.0009^a	24 (21-24)	0.5082^a

Continuous variables: Median (range); Statistical analysis:

^aAnalysis of variance;

^bχ² test;

^cFisher’s exact test; SVR: Sustained virologic response.

Citation: Okushin H, Morii K, Uesaka K, Yuasa S. Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C. World J Hepatol 2010; 2(6): 226-232
URL: https://www.wjgnet.com/1948-5182/full/v2/i6/226.htm
DOI: https://dx.doi.org/10.4254/wjh.v2.i6.226